Abstract
To the Editor: Makkar et al. (Nov. 19 issue)1 report possible subclinical leaflet thrombosis in up to 40% of patients involved in a clinical trial of transcatheter aortic-valve replacement (TAVR). In contrast, we found a relatively low incidence (7%) of possible subclinical valve leaflet thrombosis among patients in our series in which 255 patients underwent TAVR with the use of a CoreValve prosthesis. A retrospective review of our series (unpublished data) showed that in 104 patients, cardiac computed tomography (CT) at a median of 7 days after implantation (range, 3 to 87) (in 51 patients), transesophageal echocardiography at a median . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
